Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
LA JOLLA, Calif., Oct. 31, 2016 -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 9th European Scientific Oncology Conference. Antonio Gualberto, M.D., Ph.D., Chief Medical Officer, will participate and give a presentation entitled “Targeting the RAS-ERK Pathway” on Friday, November 4, 2016. The conference will be held November 3-4, 2016 in Marbella, Spain.
Dr. Gualberto’s slide presentation will be available shortly after the session in the Scientific Presentations and Papers section of Kura Oncology's website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. The preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL program. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849-5375 [email protected]
